补充性捐献人乳与早产儿配方奶对极低出生体重儿18个月龄神经发育影响的随机临床试验
这项在加拿大安大略省4个新生儿病房开展的实用双盲随机试验,将363名极低出生体重儿随机分为补充捐献人乳组(181名)和早产儿配方奶组(182名),在母乳不足时喂养90天或至出院。18个月矫正年龄时,两组在贝利-III认知、语言和运动复合评分上均无统计学显著差异,死亡与发病率指数及生长z评分变化也无显著差异。
要点
- 补充捐献人乳与早产儿配方奶相比,18个月矫正年龄贝利-III认知复合评分无统计学显著差异(校正均差-2.0,95%CI -5.8至1.8)。
- 语言和运动复合评分两组间也无统计学显著差异(校正均差分别为-3.1和-3.7,95%CI均跨0)。
- 死亡与发病率指数阳性率捐献人乳组43% vs 配方奶组40%,无统计学显著差异;生长z评分变化无显著差异。
核心结论
- 在极低出生体重儿中,与配方奶相比,使用补充性捐献人乳并未改善18个月矫正年龄时的神经发育。
- 若在母乳供应充足的环境中应用捐献人乳,不应将此神经发育结局视为治疗目标。
研究设计与样本
- 实用双盲随机临床试验,从加拿大安大略省4个新生儿病房招募极低出生体重儿,于出生后96小时内入组,招募时间为2010年10月至2012年12月,随访于2015年7月完成。
- 840名合格婴儿中363名(43.2%)被随机分组,捐献人乳组181名,早产儿配方奶组182名;存活者中299名(92%)接受了神经发育评估。
- 干预为在母乳不可用时喂养捐献人乳或配方奶90天或至出院。
- 婴儿平均出生体重996克(标准差272),平均胎龄27.7周(标准差2.6),195名(53.7%)为男性。
主要发现
- 贝利-III认知复合评分校正后捐献人乳组92.9 vs 配方奶组94.5,完全校正均差-2.0(95%CI -5.8至1.8),无统计学显著差异。
- 贝利-III语言复合评分校正后捐献人乳组87.3 vs 配方奶组90.3,完全校正均差-3.1(95%CI -7.5至1.3),无统计学显著差异。
- 贝利-III运动复合评分校正后捐献人乳组91.8 vs 配方奶组94.0,完全校正均差-3.7(95%CI -7.4至0.09),无统计学显著差异。
- 死亡与发病率指数阳性率捐献人乳组43% vs 配方奶组40%,无统计学显著差异;生长z评分变化无统计学显著差异。
临床怎么用
- 作者认为,在极低出生体重儿中,与配方奶相比,使用补充性捐献人乳并未改善18个月矫正年龄时的神经发育。
- 作者指出,若在母乳供应充足的环境中应用捐献人乳,不应将此神经发育结局视为治疗目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For many very low-birth-weight (VLBW) infants, there is insufficient mother's milk, and a supplement of pasteurized donor human milk or preterm formula is required. Awareness of the benefits of mother's milk has led to an increase in use of donor milk, despite limited data evaluating its efficacy. OBJECTIVE: To determine if nutrient-enriched donor milk compared with formula, as a supplement to mother's milk, reduces neonatal morbidity, supports growth, and improves neurodevelopment in VLBW infants. DESIGN, SETTING, AND PARTICIPANTS: In this pragmatic, double-blind, randomized trial, VLBW infants were recruited from 4 neonatal units in Ontario, Canada, within 96 hours of birth between October 2010 and December 2012. Follow-up was completed in July 2015. INTERVENTIONS: Infants were fed either donor milk or formula for 90 days or to discharge when mother's milk was unavailable. MAIN OUTCOMES AND MEASURES: The primary outcome was the cognitive composite score on the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) at 18 months' corrected age (standardized mean, 100 [SD, 15]; minimal clinically important difference, 5 points). Secondary outcomes included Bayley-III language and motor composite scores, growth, and a dichotomous mortality and morbidity index. RESULTS: Of 840 eligible infants, 363 (43.2%) were randomized (181 to donor milk and 182 to preterm formula); of survivors, 299 (92%) had neurodevelopment assessed. Mean birth weight and gestational age of infants was 996 (SD, 272) g and 27.7 (2.6) weeks, respectively, and 195 (53.7%) were male. No statistically significant differences in mean Bayley-III cognitive composite score (adjusted scores, 92.9 in donor milk group vs 94.5 in formula group; fully adjusted mean difference, -2.0 [95% CI, -5.8 to 1.8]), language composite score (adjusted scores, 87.3 in donor milk group vs 90.3 in formula group; fully adjusted mean difference, -3.1 [95% CI, -7.5 to 1.3]), or motor composite score (adjusted scores, 91.8 in donor milk group vs 94.0 in formula group; fully adjusted mean difference, -3.7 [95% CI, -7.4 to 0.09]) were observed between groups. There was no statistically significant difference in infants positive for the mortality and morbidity index (43% in donor milk group, 40% in formula group) or changes in growth z scores. CONCLUSIONS AND RELEVANCE: Among VLBW infants, use of supplemental donor milk compared with formula did not improve neurodevelopment at 18 months' corrected age. If donor milk is used in settings with high provision of mother's milk, this outcome should not be considered a treatment goal. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN35317141.
引用
- O'Connor DL, Gibbins S, Kiss A, et al. Effect of Supplemental Donor Human Milk Compared With Preterm Formula on Neurodevelopment of Very Low-Birth-Weight Infants at 18 Months: A Randomized Clinical Trial. JAMA. 2016. PMID: 27825008. doi:10.1001/jama.2016.16144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。